Voyageur Pharmaceuticals Ltd.
VM.V
TSX
08/31/2024 | 05/31/2024 | 02/29/2024 | 11/30/2023 | 08/31/2023 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | 982.70K | 835.50K | 886.80K | 908.10K | 1.09M |
Depreciation & Amortization | 1.30K | 1.40K | 1.50K | 1.60K | 1.70K |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 984.00K | 836.90K | 888.30K | 909.70K | 1.10M |
Operating Income | -984.00K | -836.90K | -888.30K | -909.70K | -1.10M |
Income Before Tax | -1.13M | -962.00K | -1.01M | -1.04M | -1.26M |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | -1.13 | -0.96 | -1.01 | -1.04 | -1.26 |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -1.13M | -962.00K | -1.01M | -1.04M | -1.26M |
EBIT | -984.00K | -836.90K | -888.30K | -909.70K | -1.10M |
EBITDA | -982.70K | -835.50K | -886.80K | -908.10K | -1.09M |
EPS Basic | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
Normalized Basic EPS | -0.01 | 0.00 | 0.00 | 0.00 | -0.01 |
EPS Diluted | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
Normalized Diluted EPS | -0.01 | 0.00 | 0.00 | 0.00 | -0.01 |
Average Basic Shares Outstanding | 543.76M | 537.02M | 530.84M | 521.88M | 500.84M |
Average Diluted Shares Outstanding | 543.76M | 537.02M | 530.84M | 521.88M | 500.84M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |